News
Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting
October 2, 2026
Read More
Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma
August 5, 2026
Read More
Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million
August 3, 2026
Read More
ABOUT US
We are pioneers in TIL cell therapy
Leading the next generation of engineered cell therapies.
Our Platform
Our proprietary
cytoDRiVE platform
Leverages drug-responsive domains (DRDs) to regulate protein function using an FDA-approved small-molecule drug.
OBSIDIAN CAREERS
Join our team
Join our collaborative team of innovators who are motivated by a sense of urgency to help patients in need.
Our collective knowledge, capabilities, intellect and energy is our greatest strength.